Following speculation and rumor ahead of the weekend, Kirin Holdings, the parent of Japanese beer giant Kirin Brewery, confirmed at a Tokyo press conference on October 22 that it plans to acquire 50.1% of Kyowa Hakko Kogyo through a takeover bid and a stock swap between the latter and Kirin Pharma, the brewer's pharmaceutical subsidiary.
Although financial terms of the deal were not disclosed, pre-confirmation speculation valued the transaction at around 300.0 billion yen ($2.55 billion).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze